Geode Capital Management LLC lifted its stake in Genocea Biosciences, Inc. (NASDAQ:GNCA) by 4.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 148,370 shares of the biotechnology company’s stock after buying an additional 6,708 shares during the quarter. Geode Capital Management LLC owned approximately 0.52% of Genocea Biosciences worth $903,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Segantii Capital Management Ltd purchased a new position in shares of Genocea Biosciences in the first quarter valued at approximately $160,000. FMR LLC increased its holdings in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock valued at $26,033,000 after purchasing an additional 18,574 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Genocea Biosciences in the first quarter valued at approximately $217,000. Keybank National Association OH acquired a new stake in shares of Genocea Biosciences in the first quarter valued at approximately $147,000. Finally, Ameriprise Financial Inc. increased its holdings in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 5,068 shares during the last quarter. Institutional investors own 59.25% of the company’s stock.
Several research firms have issued reports on GNCA. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Tuesday, June 6th. Cowen and Company reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $18.00 target price (up from $17.00) on shares of Genocea Biosciences in a report on Tuesday, July 25th. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Finally, Needham & Company LLC raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.52.
Shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) traded down 0.76% during trading on Friday, reaching $5.22. The company had a trading volume of 110,672 shares. The stock’s market capitalization is $149.42 million. The stock has a 50 day moving average of $4.82 and a 200 day moving average of $5.53. Genocea Biosciences, Inc. has a 52-week low of $3.28 and a 52-week high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). Equities research analysts forecast that Genocea Biosciences, Inc. will post ($1.98) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Genocea Biosciences, Inc. (NASDAQ:GNCA) Shares Bought by Geode Capital Management LLC” was first reported by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://baseballnewssource.com/markets/genocea-biosciences-inc-gnca-stake-lifted-by-geode-capital-management-llc/1603797.html.
In related news, CFO Jonathan Poole sold 45,000 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the sale, the chief financial officer now directly owns 84,247 shares of the company’s stock, valued at $505,482. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 6.70% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with our FREE daily email newsletter.